Your session is about to expire
← Back to Search
Intratumoral Ipilimumab for Squamous Cell Carcinoma
Study Summary
This trial is for patients with squamous cell carcinoma of the head and neck. It will test if it's possible to give ipilimumab, a cancer treatment, before surgery. The goal is to see if the patient's immune system responds to the treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a history of serious digestive system issues.I agree not to try to father a child for 165 days after treatment ends.I agree not to become pregnant for 105 days after treatment ends.I don't have conditions like bleeding, infections, colitis, or mental health issues that would make it unsafe for me to join the study.I do not have an active autoimmune or infectious disease like HIV, HBV, or HCV.I am over 18 and can understand and agree to the study's requirements.I understand the risks and investigational nature of the therapy despite my psychiatric history.My doctor thinks I'm fit enough for this study.I take 20mg or more of oral steroids daily for chronic conditions; I may use inhaled steroids.I am scheduled for surgery on my head or neck cancer and can safely have a biopsy and treatment injected directly into the tumor.
- Group 1: Intratumoral Ipilimumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of participants in this particular investigation?
"Affirmative. According to clinicaltrials.gov, this trial is still enrolling patients after commencing on November 18th 2016 and being updated as recently as January 31st 2022. There are only 18 slots available at a single medical centre."
Are volunteers still welcome to join this clinical research?
"According to clinicaltrials.gov, this trial has been recruiting since November 18th 2016 and was last updated on January 31st 2022."
What side effects have been reported with Intratumoral Ipilimumab treatments?
"Due to the limited amount of data available, Intratumoral Ipilimumab has been given a safety score of one. It is currently in Phase 1 trials and lacks evidence regarding its efficacy or safety."
Can you provide insight into any prior research endeavors involving Intratumoral Ipilimumab?
"At present, there are 318 clinical trials investigating the effects of Intratumoral Ipilimumab. 38 of these studies have reached Phase 3 and 20362 medical facilities across the globe are participating in their research. The bulk of sites conducting this scientific analysis is located in Pittsburgh, Pennsylvania."
In what scenarios is Intratumoral Ipilimumab employed?
"Intratumoral ipilimumab is regularly administered to patients with cutaneous melanoma, yet it may also provide therapeutic benefits for those in need of complete resection, liver carcinoma and metastatic melanoma treatment."
Share this study with friends
Copy Link
Messenger